Day: June 12, 2024

Stolt-Nielsen to host Capital Markets Day Today, June 12, 2024

LONDON, June 12, 2024 – Stolt-Nielsen Limited (Oslo Børs: SNI) announced that it will hold its Capital Markets Day 2024 today at 11.00 CET. Opening​, Niels G. Stolt-Nielsen, Chairman, Stolt-Nielsen​ Strategy​, Udo Lange, Chief Executive Officer, Stolt-Nielsen​ ​Stolt Tankers​, Maren Schroeder, Chief Operating Officer and Bjarke Nissen, Chief Commercial Officer, Stolt Tankers​ Stolthaven Terminals​, Guy Bessant, President, Stolthaven Terminals​ Stolt Tank Containers​, Hans Augusteijn, President, Stolt Tank Containers​ ​Stolt Sea Farm​, Jordi Trias, President, Stolt Sea Farm​ Stolt Investments​, Alex Ng, VP Corporate Development & Strategy, ​Stolt-Nielsen​ ​Capital Allocation​, Jens F. Grüner-Hegge, Chief Financial Officer, ​Stolt-Nielsen ​Closing and Q & A, Udo Lange, Chief Executive Officer, Stolt-Nielsen​ As part of today’s...

Continue reading

SIKA OPENED NEW STATE-OF-THE-ART PLANT IN NORTHEAST CHINA

SIKA OPENED NEW STATE-OF-THE-ART PLANT IN NORTHEAST CHINA Sika opened a new plant in Liaoning, the largest province in northeastern China. This site will manufacture a full range of products, including mortars, tile adhesives, and waterproofing solutions. This highly efficient new plant enables Sika to meet the market demands, whilst significantly reducing logistical distances. The Liaoning plant will cater to Sika customers in three provinces in northeastern China, with a population of more than 98 million, as well as east-central Mongolia. In addition to state-of-the-art production lines, the new facility provides office spaces, laboratories, warehousing, and logistics. Currently, Sika has 34 manufacturing sites in China and has been active in the Chinese market for over three decades. Philippe Jost, Regional Manager Asia/Pacific: “The...

Continue reading

Coop Pank AS results for May 2024

Coop Pank’s financial results in May 2024: In May, number of the bank’s clients increased by 2,300 and number of active clients increased by 1,300. By the end of the month number of clients reached 194,100 and number of active clients reached 87,200. Over the year, customer base has grown by 21%. Volume of the bank’s customer deposits increased by 7 million euros, reaching 1.74 billion euros by the end of month. Deposits of corporate customers remained stable and deposits of private customers increased by 4 million euros. The volume of deposits attracted from international platforms increased by 3 million euros. Over the year, volume of bank deposits has grown by 11%. The bank’s loan portfolio increased by 33 million euros and reached 1.59 billion euros by the end of month. Business loans increased by 16 million euros,...

Continue reading

Ascom signs a five-year contract with Children’s Health Ireland to support the digitalization of their hospitals

New Children’s Hospital Ireland Construction site of the new Children Hospital of CHI in Dublin, Ireland Ascom signed a five-year contract with Children’s Health Ireland (CHI). The partnership will see the implementation of Ascom’s cutting-edge Alerts and Notification Management System (ANMS) in the new Children’s Hospital project. The implementation represents a pivotal step in CHI’s comprehensive digital transformation initiative towards a fully digital, paperless hospital environment. Ascom’s ANMS will serve as the critical component in CHI’s transformative vision that connects clinical and non-clinical staff with various alarm sources within the hospital. Built on the Ascom Healthcare Platform, the state-of-the-art solution empowers healthcare professionals to make informed decisions through efficient delivery, acknowledgment,...

Continue reading

WISeKey Integrates DePIN on OISTE-WISeKey Cryptographic Root of Trust

Integration advances Secure Infrastructure Development Geneva, Switzerland – June 12, 2024 – WISeKey International Holding Ltd. (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a global leader in cybersecurity, digital identity, and Internet of Things (IoT), today announced that it has integrated DePIN on its unparalleled trusted security framework, the OISTE-WISeKey Cryptographic Root of Trust (RoT). This strategic advancement aims to leverage the unique advantages of Swiss bunkers for secure operations, paving the way for a new era of infrastructure development. In a world increasingly reliant on digital and physical interconnectedness, the integration of WISeKey’s RoT with DePIN’s decentralized approach marks a significant leap forward. This synergy will enable the creation of decentralized applications (dApps) that use tokens to incentivize...

Continue reading

BioSenic to host Annual General Meeting on July 12, 2024

PRESS RELEASE – REGULATED INFORMATION Preliminary documents for the Annual General Meeting have been made available on company’s website Mont-Saint-Guibert, Belgium, June 12th, 2024 7.00am CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases and cell repair, invites its shareholders and the holders of registered subscription rights and registered convertible bonds of the Company to the annual general meeting to be held on 12 July 2024 as from 11:00 am CET, at Osborne Clarke offices, Bastion Tower, Place du Champ de Mars 5, 1050 Brussels, Belgium. The notice for the annual general meeting, including the agenda of the day as well as the text of the resolution proposals, is published today in the Belgian Official Gazette and La Libre Belgique. The documents...

Continue reading

Junshi Biosciences Announces Phase 3 Study of Toripalimab Combined with Bevacizumab for the First-line Treatment of Advanced Hepatocellular Carcinoma Meets Primary Endpoint

SHANGHAI, June 11, 2024 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the primary endpoints of progression-free survival (“PFS,” based on independent radiographic review) and overall survival (“OS”) of a multi-center, randomized, open-label, active-controlled phase III clinical study (the “HEPATORCH study,” NCT04723004) of the company’s product, toripalimab (trade name: TUOYI®, product code: JS001), in combination with bevacizumab for the first-line treatment of advanced hepatocellular carcinoma (“HCC”) has met the pre-defined efficacy boundary. Junshi Biosciences plans to submit a supplemental new drug application (“NDA”)...

Continue reading

Planet 13 Announces Results of Annual General Meeting

LAS VEGAS, June 11, 2024 (GLOBE NEWSWIRE) — Planet 13 Holdings Inc. (CSE: PLTH) (OTCQX: PLNH) (“Planet 13” or the “Company”), a leading vertically-integrated multi-state cannabis company, today announced the following results for each item of business considered at Planet 13’s Annual General Meeting of Stockholders held on Tuesday, June 11, 2024. Election of Directors The following table sets out the percentage of shares of common stock voted in respect of the election of directors. Nominee % For % Withheld Robert Groesbeck 98.63% 1.37% Larry Scheffler 98.54% 1.46% Lee Fraser 97.31% 2.69% Adrienne O’Neal 98.99% 1.01% Kevin Martin 99.33% 0.67% Ratification of Auditors The following table sets out the percentage of shares of common stock voted in respect of the ratification of the appointment of Davidson & Company...

Continue reading

ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering

WINSTON-SALEM, N.C., June 11, 2024 (GLOBE NEWSWIRE) — ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease, today announced the pricing of an underwritten public offering and a concurrent registered direct offering of 53,719,009 shares of its Class A ordinary shares at a price of $2.42 per share, before applicable underwriting discounts and commissions. In addition, the underwriters will have a 30-day option to purchase up to an additional 15% of the Class A ordinary shares sold in the underwritten public offering. All of the Class A ordinary shares in the underwritten public offering and concurrent registered direct offering are being sold by the Company. The public offering and the concurrent registered direct offering are...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.